C-nitroso-derived nitroxyl donors
AssigneeWake Forest University Health Sciences
InventorS. Bruce King
Life of this patent
Estimating the term…
Abstract
Active compounds of Formula I are described: wherein: R1 and R2 are each independently C1-C4 alkyl; or R1 and R2 together form a C2-C7 alkylene chain; and Z is a non-steroidal anti-inflammatory drug (NSAID); along with pharmaceutically acceptable salts and prodrug thereof, and methods of using the same.
Claims10
A pharmaceutical composition for treating congestive heart failure, comprising, in combination, a pharmaceutically acceptable carrier and a treatment effective amount of a compound of Formula (III):
- wherein:
- R1 is C1 -C4 alkyl and R2 is selected from the group consisting of CCI3, CH2F, CHF2, CF3, CH2CF3, CF2CF3, CH2CF2CF3, CH2CH2CF3, CF2CF2CF3, CH2CH2CH2CF3CH2CH2CF2CF3, CH2CF2CF2CF3, and CF2CF2CF2CF3;
- or R1 is selected from the group consisting of CCI3, CH2F, CHF2, CF3, CH2CF3, CF2CF3, CH2CF2CF3, CH2CH2CF3, CF2CF2CF3, CH2CH2CH2CF3, CH2CH2CF2CF3,CH2CF2CF2CF3, and CF2CF2CF2CF3 and R2 is C1-C4 alkyl;
- or R1 and R2 are each independently selected from the group consisting of CCI3, CH2F, CHF2, CF3, CH2CF3, CF2CF3, CH2CF2CF3, CH2CH2CF3, CF2CF2CF3, CH2CH2CH2CF3, CH2CH2CF2CF3, CH2CF2CF2CF3, and CF2CF2CF2CF3;
- or R1 and R2 together form a C2-C7 alkylene chain;
- and
- R3 is selected from the group consisting of CCI3, CH2F, CHF2, CH2CF3,CF2CF3, CH2CH2CF3, CH2CF2CF3, CF2CF2CF3, CH2CH2CH2CF3, CH2CH2CF2CF3, CH2CF2CF2CF3, CF2CF2CF2CF3, CH2CH2CH2CH2CF3, CH2CH2CH2CF2CF3, CH2CH2CF2CF2CF3, CH2CF2CF2CF2CF3, and CF2CF2CF2CF2CF3;
- or a pharmaceutically acceptable salt or prodrug thereof.
A method of treating congestive heart failure in a subject in need thereof, comprising administering said subject a treatment effective amount of a compound of Formula (III):
- wherein:
- R1 is C1-C4 alkyl and R2 is selected from the group consisting of CCI3, CH2F, CHF 2, CF3, CH2CF3, CF2CF3, CH2CF2CF3, CH2CH2CF3, CF2CF2CF3, CH2CH2CH2CF3, CH2CH2CF2CF3, CH2CF2CF2CF3, and CF2CF2CF2CF3;
- or R1 is selected from the group consisting of CCI3, CH2F, CHF2, CF3, CH2CF3, CF2CF3 , CH2CF2CF3, CH2CH2CF3,CF2CF2CF3, CH2CH2CH2CF3, CH2CH2CF2CF3, CH2CF2CF2CF3, and CF2CF2CF2CF3 and R2 is C1-C4 alkyl;
- or R1 and R2 are each independently selected from the group consisting of CCI3, CH2F, CHF2, CF3, CH2CF3, CF2CF3, CH2CF2CF3, CH2CH2CF3, CF2CF2CF3, CH2CH2CH2CF3, CH2CH2CF2CF3, CH2CF2CF2CF3, and CF2CF2CF2CF3;
- or R1 and R2 together form a C2-C7 alkylene chain;
- and
- R3 is selected from the group consisting of CCI3,CH2F CHF2, CH2CF3, CF2CF3, CH2CH2CF3, CH2CF2CF3, CF2CF2CF3, CH2CH2CH2CF3, CH2CH2CF2CF3, CH2CF2CF2CF3, CF2CF2CF2CF3,CH2CH2CH2CH2CF3, CH2CH2CH2CF2CF3, CH2CH2CF2CF2CF3, CH2CF2CF2CF2CF3, and CF2CF2CF2CF2CF3;
- or a pharmaceutically acceptable salt or prodrug thereof.
Dependencies are inferred from the claim text.